The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Aquila Biopharmaceuticals, Inc.

Aquila Biopharmaceuticals, Inc.
 PROFILE
Aquila Biopharmaceuticals, a subsidiary of Antigenics, develops drugs to fight infectious diseases and cancer in humans and animals. Aquila's products are based on two core technologies: the CD1 system and the Stimulon family of adjuvants. QS-21, the company's lead adjuvant, is derived from the bark of the South American "Quillaja saponaria" tree. The CD1 system is a technology used to fight infectious diseases, cancers, and autoimmune disorders by presenting antigens to the blood stream through the CD1 pathway. Products in Aquila's pipeline include Quilimmune-P to prevent pneumonia in the elderly and CD1 antigens to treat such diseases as tuberculosis and chlamydia.

 COMPETITION
CEL-SCI Corporation (CVM)
Epimmune Inc. (EPMN)
Merck & Co., Inc. (MRK)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 2.10
1-Yr. Sales Growth: (62.5)%
Employees: 41
Revenue per employee: $51,219.51

 CONTACT INFO
175 Crossing Blvd.
Framingham, MA 01702
US
Phone: 508-628-0100
Fax: 508-766-2705
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001